19,663 Shares in USANA Health Sciences, Inc. (NYSE:USNA) Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,663 shares of the company's stock, valued at approximately $890,000. WINTON GROUP Ltd owned 0.10% of USANA Health Sciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its stake in USANA Health Sciences by 4.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 222,423 shares of the company's stock worth $11,922,000 after purchasing an additional 8,536 shares during the period. Dimensional Fund Advisors LP increased its stake in USANA Health Sciences by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company's stock worth $36,323,000 after purchasing an additional 21,524 shares during the period. Trexquant Investment LP purchased a new stake in USANA Health Sciences during the fourth quarter worth about $266,000. Quest Partners LLC acquired a new position in shares of USANA Health Sciences during the fourth quarter worth about $66,000. Finally, Allianz Asset Management GmbH grew its position in shares of USANA Health Sciences by 43.0% during the fourth quarter. Allianz Asset Management GmbH now owns 26,970 shares of the company's stock worth $1,446,000 after buying an additional 8,108 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

USNA has been the subject of a number of analyst reports. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 24th. DA Davidson lowered their price objective on USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating for the company in a research report on Thursday, July 25th.

USANA Health Sciences Stock Up 4.6 %

USNA traded up $1.75 on Tuesday, reaching $40.06. The company's stock had a trading volume of 150,291 shares, compared to its average volume of 78,261. The stock has a 50 day moving average of $41.25 and a two-hundred day moving average of $44.64. The company has a market capitalization of $763.14 million, a price-to-earnings ratio of 11.93, a P/E/G ratio of 1.27 and a beta of 0.90. USANA Health Sciences, Inc. has a fifty-two week low of $36.05 and a fifty-two week high of $60.90.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). The business had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same period last year, the company earned $0.89 earnings per share. As a group, analysts anticipate that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at USANA Health Sciences

In related news, Director John Turman Fleming sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company's stock, valued at $111,208.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the sale, the director now directly owns 2,503 shares of the company's stock, valued at $111,208.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the company's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 over the last three months. 0.33% of the stock is owned by corporate insiders.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.